Effects of B Cell Depleting Therapy on Prostaglandin E2 Pathway in Rheumatoid Arthritis
Author Information
Author(s): Gheorghe Karina Roxana, Thurlings Rogier M., Westman Marie, Boumans Maartje J., Malmström Vivianne, Trollmo Christina, Korotkova Marina, Jakobsson Per-Johan, Tak Paul-Peter
Primary Institution: Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden
Hypothesis
Depleting B cells could change synovial immune interactions, reduce cytokine levels, and decrease disease activity in the inflamed joint.
Conclusion
B cell depleting therapy has minimal influence on the expression of enzymes involved in the PGE2 pathway, despite clinical improvement in most rheumatoid arthritis patients.
Supporting Evidence
- B cells from synovial fluid showed higher expression of MPGES1 and COX-2 than those from peripheral blood.
- Rituximab treatment did not significantly change the expression of MPGES1, COX-1, or COX-2 in synovial tissue.
- Clinical improvement was observed in most patients despite unchanged local expression of inflammatory pathways.
Takeaway
The study found that even though a treatment that removes B cells helps patients feel better, it doesn't really change some important inflammation pathways in their joints.
Methodology
B cells were analyzed from synovial fluid and peripheral blood of RA patients using flow cytometry and immunohistochemical staining on synovial biopsies.
Potential Biases
Potential confounding factors include the use of NSAIDs and other medications that may affect PGE2 production.
Limitations
The variability in enzyme expression did not correlate with clinical outcomes, and the study could not exclude delayed effects of treatment.
Participant Demographics
Patients had active rheumatoid arthritis despite previous treatments.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website